Selected Slide Presentations
Click on the links below to view presentations.

Resistance to New Antiretroviral Agents

R1206, a representative of a new class of potent diphenylether NNRTIs broadly active against NNRTI resistant HIV-1 variants and achieving high systemic exposures and benign safety profiles in animal species
Klaus Klumpp, Roche, USA

Strategic flexibility of the nonnucleoside RT inhibitor TMC278 explains its potency against drug-resistant mutants
Kalyan Das, Rutgers Universtiy, USA

Anti-HCV activity and cellular pharmacology of 2'-methylcytidine alone and in combination with non-toxic concentrations of ribarvirin in the HCV replicon system
Brenda Hernandez-Santiago, Emory University/VA Medical Center, USA

Synergy of a hepatitis C virus NS4A antagonist, ACH-806, in combination with HCV protease or polymerase inhibitors
David Wyles, University of California, San Diego, USA

Resistance and cross-resistance to first generation integrase inhibitors: insights from a Phase 2 study of elvitegravir (GS-9137)
Damian McColl, Gilead Sciences, Inc., USA

A structural basis for resistance to PL-100
Jospeh Vacca, Merck Research Laboratories, USA

In vitro HIV-1 resistance selection to GS-8374, a novel phosphonate protease inhibitor: comparison with lopinavir, atazanavir, and darunavir
Christian Callebaut, Gilead Sciences, Inc., USA

Entry Inhibition

Current implementations of HIV genotyping algorithms are inadequate for the prediction of X4 co-receptor usage in clinical isolates from population-based V3 sequences: approaches to improvement
Viviane Lima, BC Centre for Excellence in HIV/AIDS, Canada

Detection limit of X4 minority virus in abundant R5-tropic virus populations in genotypic and phenotypic assays
Ina Vandenbroucke, Virco BVBA, Belgium

HIV Pathogenesis, Fitness and Resistance

Impact of HR1 enfuvirtide resistance mutations on sensitivity to HR2 directed neutralizing antibodies
Ashley Barry, Trimeris, Inc., USA

Mechanisms of HIV Drug Resistance

Competition with the nucleic acid substrate can present an obstacle in the development of RNase H active site inhibitors
Matthias Götte, McGill University, Canada

HIV-1 reverse transcriptase mutations A371V and Q509L decrease DNA dependent RNase H cleavage and increase AZT-MP excision
Jessica Brehm, University of Pittsburgh, USA

In vitro molecular characterization of the development of the K65R and M184V mutations in subtype C HIV-1
Dimitrios Coutsinos, McGill University AIDS Centre, Canada

New Resistance Technologies and Interpretations

Novel electrophoretic tag-based in vitro assay to quantify dimerization of p66 and p51 subunits of HIV-1 reverse transcriptase (RT)
Soumi Gupta, Monogram Biosciences, USA

Prevalence of low abundance drug resistant variants by ultra deep sequencing in chronically HIV-infected antiretroviral (ARV) naïve patients and the impact on virologic outcomes
Michael Kozal, Yale University School of Medicine, USA

DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations
Gary Wang, University of Pennsylvania School of Medicine, USA

Protease gene mutations in a trial comparing first line LPV/r monotherapy to LPV/r + AZT/3TC (MONARK Trial)
Constance Delaugerre, Hopital Ambroise Pare, France